• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Excitation dependent recombination studies on SnO2/TiO2 electrospun nanofibers?
  Veluru Jagadeesh babu,Sesha Vempati RSC Adv., 2015,5, 66367-66375
• 5. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735

Research Brief on 2,3-Difluoro-5-methoxy-4-methylbenzoic Acid (CAS: 1706446-21-0) in Chemical Biology and Pharmaceutical Applications

2,3-Difluoro-5-methoxy-4-methylbenzoic acid (CAS: 1706446-21-0) is a fluorinated benzoic acid derivative that has recently garnered attention in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound, characterized by its difluoro and methoxy substitutions, serves as a versatile intermediate in the synthesis of bioactive molecules, particularly in the development of kinase inhibitors and anti-inflammatory agents. Recent studies have explored its role in modulating protein-protein interactions and enzyme activity, positioning it as a promising scaffold for drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry highlighted the compound's utility as a building block for selective kinase inhibitors. Researchers synthesized a series of derivatives using 2,3-difluoro-5-methoxy-4-methylbenzoic acid as a core structure, demonstrating potent inhibition of tyrosine kinases involved in cancer pathways. The fluorination pattern was found to enhance binding affinity through hydrophobic interactions and fluorine-specific effects, such as orthogonal dipole stabilization. Molecular docking simulations revealed that the methoxy group contributes to optimal orientation within the ATP-binding pocket of target kinases.

In parallel, a preprint on bioRxiv (2024) investigated the compound's metabolic stability and pharmacokinetic properties. The study reported that 2,3-difluoro-5-methoxy-4-methylbenzoic acid exhibits favorable metabolic resistance to cytochrome P450 enzymes, with a half-life exceeding 6 hours in human liver microsomes. This stability, attributed to the electron-withdrawing effects of fluorine atoms and steric shielding by the methyl group, suggests its potential as a pharmacophore in orally bioavailable drugs. Researchers also noted its low cytotoxicity in HEK293 cells (IC50 > 100 μM), supporting further derivatization efforts.

Notably, the compound has emerged in proteolysis-targeting chimera (PROTAC) development, as documented in ACS Chemical Biology (2023). Its benzoic acid moiety serves as an effective linker for E3 ligase recruitment, enabling the targeted degradation of disease-relevant proteins. One optimized PROTAC incorporating this scaffold achieved >90% degradation of BRD4 at 100 nM concentration in leukemia cell lines, with demonstrated selectivity over related bromodomain proteins. The difluoro motif was critical for maintaining ternary complex stability, as confirmed by cryo-EM structural analysis.

Ongoing clinical-stage research (Phase I/II trials) by several biotech firms has extended these findings to inflammatory diseases. A patent application (WO2023187542) discloses 2,3-difluoro-5-methoxy-4-methylbenzoic acid derivatives as NLRP3 inflammasome inhibitors, showing nanomolar potency in suppressing IL-1β release in macrophage assays. The methoxy group's role in membrane permeability was quantitatively validated through artificial membrane permeability assays (PAMPA), with Pe values correlating with in vivo anti-inflammatory efficacy in murine models.

From a synthetic chemistry perspective, recent advances in late-stage fluorination (Nature Chemistry, 2024) have improved access to this scaffold. A novel palladium-catalyzed C-H fluorination protocol enables direct conversion of methoxybenzoates to the difluoro product with 82% yield, addressing previous challenges in regioselectivity. This methodological breakthrough supports structure-activity relationship (SAR) studies by allowing rapid analog generation.

In conclusion, 2,3-difluoro-5-methoxy-4-methylbenzoic acid represents a multifaceted tool in modern drug discovery, with demonstrated applications spanning kinase inhibition, targeted protein degradation, and immunomodulation. Its balanced physicochemical properties and synthetic tractability position it as a valuable scaffold for next-generation therapeutics. Future research directions may explore its incorporation into bifunctional molecules and investigation of fluorine-specific biology, particularly in the context of membrane receptor modulation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)